Vistin Pharma
ISIN: NO0010734122 | Ticker: VISTN | LEI: 5967007LIEEXZXFQY092
Country: Norway
We are a Norwegian pharmaceutical company. As a dedicated European producer of high quality Metformin, we are well positioned to supply the growing global market.
Vistin Pharma today produce about 10% of the world’s demand for Metformin HCl API and have in 2022 initiated a project to double the manufacturing capacity. Our Metformin is also available as direct compressible lubricated granules. Vistin Pharma Headquarter is located in Oslo, Norway. Our manufacturing facility is located in Kragerø, Norway. The facility is certified according to current Good Manufacturing Practice (cGMP) and successfully inspected by the US Food and Drug Administration (FDA).
Vistin Pharma AS was established in June 2015, when Vistin Pharma AS acquired the B2B business of Weifa AS.
2015
Served areaWorldwide
HeadquartersPostboks 6735 Etterstad, 0609 Oslo – Norway
| Line item in (nok) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 321,915,000.00 | 333,147,000.00 | 407,213,000.00 |
| Noncurrent Assets | N/A | 180,389,000.00 | 195,316,000.00 | 248,031,000.00 |
| Property Plant And Equipment | N/A | 145,261,000.00 | 167,457,000.00 | 219,430,000.00 |
| Deferred Tax Assets | N/A | 35,128,000.00 | 27,858,000.00 | 28,601,000.00 |
| Current Assets | N/A | 141,526,000.00 | 137,831,000.00 | 159,182,000.00 |
| Inventories | N/A | 31,788,000.00 | 42,907,000.00 | 83,446,000.00 |
| Current Trade Receivables | N/A | 30,400,000.00 | 40,245,000.00 | 66,155,000.00 |
| Other Current Receivables | N/A | 2,302,000.00 | 18,933,000.00 | 8,146,000.00 |
| Cash and cash equivalents | 319,673,000.00 | 77,036,000.00 | 35,746,000.00 | 1,435,000.00 |
| Equity And Liabilities | N/A | 321,915,000.00 | 333,147,000.00 | 407,213,000.00 |
| Equity | 413,396,000.00 | 272,405,000.00 | 275,768,000.00 | 273,263,000.00 |
| Issued Capital | N/A | 44,345,000.00 | 44,345,000.00 | 44,345,000.00 |
| Retained Earnings | N/A | -996,000.00 | 24,538,000.00 | 22,033,000.00 |
| Share Premium | N/A | 229,056,000.00 | 206,885,000.00 | 206,885,000.00 |
| Additional Paidin Capital | N/A | 0.00 | 0.00 | N/A |
| Liabilities | N/A | 49,509,000.00 | 57,378,000.00 | 133,950,000.00 |
| Noncurrent Liabilities | N/A | 17,306,000.00 | 16,343,000.00 | 16,155,000.00 |
| Noncurrent Recognised Liabilities Defined Benefit Plan | N/A | 16,330,000.00 | 15,831,000.00 | 13,199,000.00 |
| Other Noncurrent Liabilities | N/A | 976,000.00 | 512,000.00 | 2,956,000.00 |
| Current Liabilities | N/A | 32,204,000.00 | 41,035,000.00 | 117,795,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 17,893,000.00 | 20,808,000.00 | 25,906,000.00 |
| Current Tax Liabilities Current | N/A | 0.00 | 0.00 | N/A |
| Other Current Liabilities | N/A | 14,311,000.00 | 20,227,000.00 | 46,748,000.00 |
| Line item in (nok) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 253,159,000.00 | 275,812,000.00 | 287,675,000.00 |
| Other Income | 747,000.00 | 2,811,000.00 | 17,177,000.00 |
| Raw Materials And Consumables Used | 73,288,000.00 | 96,097,000.00 | 138,064,000.00 |
| Employee Benefits Expense | 72,499,000.00 | 73,426,000.00 | 78,972,000.00 |
| Depreciation Amortisation And Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss | 9,623,000.00 | 10,609,000.00 | 12,280,000.00 |
| Other Expense By Nature | 52,940,000.00 | 65,241,000.00 | 81,632,000.00 |
| Profit Loss From Operating Activities | 45,555,000.00 | 33,250,000.00 | -6,095,000.00 |
| Finance Income | 14,066,000.00 | 6,067,000.00 | 9,554,000.00 |
| Finance Costs | 183,893,000.00 | 7,322,000.00 | 9,466,000.00 |
| Profit Loss Before Tax | -124,272,000.00 | 31,995,000.00 | -6,008,000.00 |
| Income Tax Expense Continuing Operations | -27,317,000.00 | 7,129,000.00 | -1,293,000.00 |
| Profit (loss) | -96,955,000.00 | 24,867,000.00 | -4,716,000.00 |
| Line item in (nok) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -96,955,000.00 | 24,867,000.00 | -4,716,000.00 |
| Adjustments For Decrease Increase In Inventories | N/A | -7,681,000.00 | -11,118,000.00 | -40,540,000.00 |
| Cash Flows From Used In Operating Activities | N/A | -145,731,000.00 | 13,681,000.00 | -10,510,000.00 |
| Interest Received Classified As Investing Activities | N/A | 1,725,000.00 | 265,000.00 | 28,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -51,378,000.00 | -31,675,000.00 | -64,262,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 430,000.00 | 836,000.00 | 2,589,000.00 |
| Dividends Paid Classified As Financing Activities | N/A | 44,345,000.00 | 22,173,000.00 | 0.00 |
| Interest Paid Classified As Financing Activities | N/A | 753,000.00 | 289,000.00 | 2,092,000.00 |
| Cash Flows From Used In Financing Activities | N/A | -45,528,000.00 | -23,298,000.00 | 40,460,000.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | -242,638,000.00 | -41,292,000.00 | -34,312,000.00 |
| Cash and cash equivalents | 319,673,000.00 | 77,036,000.00 | 35,746,000.00 | 1,435,000.00 |
Please note that some sums might not add up.
NO0010734122
LEI5967007LIEEXZXFQY092
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.